ALung Technologies, Inc.

When ALung Technologies Inc. was selected in 2015 by US FDA to participate in the agency's Expedited Access Pathway program for its novel Hemolung device, the firm wasn't necessarily sure what it

ALung Technologies Inc. CEO Pete DeComo, whose novel Hemolung device has treated roughly 900 patients worldwide and is the subject of landmark clinical trials in the US and the UK, says the artific

Device Transactions Continuing the downward trend in financing over the past several quarters, the device industry collected $1.2 billion in Q2 funding, a 48% decrease from Q1's $2.3 billion total. It

Several smaller, venture-backed medtech players initiated new clinical trials in July, as recorded by Informa's Meddevicetracker . Among the notable studies started last month are Bigfoot Biomedi